As of 9:40 a.m. on October 14, the share price of S-Biomedics on the KOSDAQ market was up 8.15% from the previous day's closing price, reaching 29,850 won. This appears to be due to the announcement of clinical trial results for Parkinson's disease patients.
On this day, S-Biomedics announced that the results confirming the safety and efficacy of using human embryonic stem cell-derived dopaminergic neurons in clinical trials for Parkinson's disease patients have been published in the world-renowned scientific journal Cell.
This is based on the one-year follow-up results after intracerebral transplantation of dopaminergic cells in 12 subjects (six with low doses and six with high doses) conducted at Yonsei University Severance Hospital. This clinical trial using embryonic stem cell-derived dopaminergic cells for Parkinson's disease is the second in the world and the first in Asia.
The joint research team, consisting of Severance Hospital and S-Biomedics, received Phase 1/2a clinical trial approval from the Ministry of Food and Drug Safety and completed the administration of the dopaminergic cell therapy to the clinical subjects.
According to the company, among the patients who received the cell transplants, there was a case where a patient who had stopped conducting an orchestra due to Parkinson's disease was able to pick up the baton again, and another case where a patient who had difficulty moving due to frequent falls and unstable posture was able to recover enough to enjoy a local festival with friends. In addition, a patient who previously found it difficult to walk is now able to enjoy playing table tennis and badminton.
Regarding safety, no unusual side effects related to cell transplantation were observed in any of the patients. To date, among the 12 patients who received transplants, one experienced minor bleeding in an area unrelated to the transplantation site, but no unusual neurological findings or side effects were observed.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
